Alicyclic Ring Containing Patents (Class 514/690)
-
Publication number: 20090263522Abstract: A novel formulation is provided that serves to inhibit the inflammatory response in animals. The formulation comprises, as a first component an effective amount of a curcuminoid species and an effective amount of a second component selected from the group consisting of an alpha-acid species or a beta-acid species or derivatives thereof. The composition provides synergistic anti-inflammatory effects in response to physical or chemical injury or abnormal immune stimulation due to a biological agent or unknown etiology.Type: ApplicationFiled: November 14, 2005Publication date: October 22, 2009Inventors: John G. Babish, Terrence M. Howell, Linda M. Pacioretty
-
Patent number: 7605183Abstract: A method for inhibiting or blocking molecular generating and/or inducing functions of molecules using an inhibitory or blocking agent of the formula: wherein R1-6 are as defined herein.Type: GrantFiled: August 9, 2007Date of Patent: October 20, 2009Inventors: Shozo Koyama, Yoshihiro Yamaguchi
-
Publication number: 20090257996Abstract: Dietary supplements—providing energy and strengthening skeletal muscles and facilitating skeletal muscles ability to sustain prolonged periods of physical activity—containing propionyl-L-carnitine or one of its salts, coenzyme Q10, nicotinamide, riboflavin, pantothenic acid and optionally other components such as amino acids and creatines.Type: ApplicationFiled: September 20, 2006Publication date: October 15, 2009Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.Inventor: Franco Gaetani
-
Publication number: 20090252807Abstract: The present invention is directed to compositions comprising a nanoparticulate prostaglandin derivative, preferably limaprost or a salt or derivative thereof, having improved bioavailability. The nanoparticulate prostaglandin derivative particles of the composition have an effective average particles size of less than about 2000 nm and are useful in the treatment of ischemic symptoms. The invention also relates to a controlled release composition comprising a prostaglandin derivative, such as limaprost alfadex, or a nanoparticulate prostaglandin derivative, such as limaprost or a salt or derivative thereof, that in operation delivers the drug in a pulsed or bimodal manner for the treatment of ischemic symptoms.Type: ApplicationFiled: April 13, 2006Publication date: October 8, 2009Applicant: ELAN PHARMA INTERNATIONAL LIMITEDInventors: Scott Jenkins, Gary Liversidge
-
Publication number: 20090239953Abstract: The present invention relates to a compound represented by the formula (I), method of preparation, pharmaceutical preparation containing said compound, and the use of said compound in the manufacture of a pharmaceutical preparation for the prevention and treatment of cancer by way of inhibiting the proliferation of carcinoma cells of the cervix and ovaries.Type: ApplicationFiled: November 20, 2007Publication date: September 24, 2009Inventors: Ahmad Bustamam Abdul, Muhammad Nazrul Hakim Abdullah, Mohd Nordin Lajis, Nirmala Devi Tailan, Zetty Nadia Mohd Zain, Siddig Ibrahim Abdel Wahab, Adel Sharaf Al-Zubairi
-
Patent number: 7589123Abstract: Compounds of general formula I: wherein: R1 and R2 are, independently of each other, selected from hydrogen, optionally substituted C1-10alkyl, optionally substituted —CO—(C1-10alkyl), optionally substituted C3-10cycloalkyl, optionally substituted —CO—(C3-10cycloalkyl), optionally substituted C2-10alkenyl, optionally substituted —CO—(C2-10alkenyl), optionally substituted aryl, and optionally substituted —CO-aryl, or R1 and R2 together represent an optionally substituted saturated or unsaturated C1-10alkylidene group, or an optionally substituted saturated or unsaturated C3-10cycloalkylidene group, or R1 and R2 together with the carbon atom to which they are attached represent an optionally substituted saturated or unsaturated organic ring containing 3, 4, 5, 6, 7 or 8 ring carbon atoms and optionally 1, 2 or 3 ring heteroatoms selected from O, N and S; R3, which may be the same as, or different from, either of R1 and R2, is selected from optionally substituted C1-10alkyl, optionally substituted C3-10cyclType: GrantFiled: July 5, 2007Date of Patent: September 15, 2009Assignee: Phytopharm PLCInventors: Daryl David Rees, Phillip James Gunning, Antonia Orsi, Patrick A. Howson, Paul Barraclough, Noelle Callizot
-
Patent number: 7586008Abstract: The invention provides para substituted dialkylphenol derivatives of propofol. The invention further provides pharmaceutical compositions comprising such analogs, methods for preparing such analogs, and methods of using such analogs to induce general anesthesia, sedation, and/or hypnotic or sleep effects in a patient.Type: GrantFiled: July 9, 2008Date of Patent: September 8, 2009Assignee: Abraxis Bioscience, Inc.Inventors: Chunlin Tao, Cheng Zhi Yu, Neil P. Desai, Vuong Trieu
-
Patent number: 7579016Abstract: A method for for repelling arthropods involving treating an object or area with an arthropod repelling effective amount of at least one isolongifolenone analog (and optionally a carrier or carrier material).Type: GrantFiled: April 21, 2008Date of Patent: August 25, 2009Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Aijun Zhang, John F. Carroll, Shifa Wang, Jerome A. Klun
-
Publication number: 20090197939Abstract: A method for treating skin, reducing oxidative damage to a skin cell, reducing lipoxygenase (LO) activity in a skin cell, reducing cyclooxygenase (COX) activity in a skin cell, reducing tumor necrosis factor alpha (TNF-?) in a skin cell, or reduction matrix metalloproteinase enzyme activity in a skin cell comprising contacting skin or a skin cell with an aromatic skin-active ingredient.Type: ApplicationFiled: April 18, 2008Publication date: August 6, 2009Applicant: MARY KAY INC.Inventors: Bob Walke, Cristi Gomez, Tiffany C. Florence, Michelle D. Hines
-
Patent number: 7566737Abstract: The invention concerns novel substituted 1,3-diphenylprop-2-en-1-one derivatives and combinations of said derivatives with other therapeutically active ingredients. The invention also concerns compositions comprising said derivatives or said combinations and uses thereof, for the treatment of cerebrovascular diseases, pathology related to inflammation, neurodegeneration, deregulations of lipid and/or glucose metabolism, cell proliferation and/or differentiation and/or skin or central nervous system ageing.Type: GrantFiled: July 26, 2006Date of Patent: July 28, 2009Assignee: GenfitInventors: Jean-François Delhomel, Karine Caumont-Bertrand
-
Publication number: 20090169591Abstract: In accordance with one aspect of the invention, implantable and insertable medical articles are provided which are useful for the local treatment of tumors. These medical articles comprise one or more active agents that influence the local tumor environment in vivo, for example, decreasing the level of nutrients in the local tumor environment, inhibiting the utilization of nutrients in the local tumor environment, decreasing the amount of molecular oxygen and/or reactive oxygen species in the local tumor environment, or increasing the amount of molecular oxygen and/or reactive oxygen species in the local tumor environment. Other aspects of the invention pertain to methods of treatment that employ such medical articles. Still other aspects of the invention pertain to methods of making such medical articles.Type: ApplicationFiled: December 19, 2008Publication date: July 2, 2009Applicant: BOSTON SCIENTIFIC SCIMED, INC.Inventors: Goldi Kaul, John E. O'Gara
-
Publication number: 20090148426Abstract: The present invention relates to a composition for life extension, comprising reduced coenzyme Q10 as an active ingredient, as well as relates to a method of extending a life span using the composition comprising reduced coenzyme Q10 as an active ingredient. In the present invention, it has been found that long-term ingestion of feed that contains reduced coenzyme Q10 enables the life span of senescence-accelerated model mice to be extended. No sign indicating toxicity is observed in the senescence-accelerated model mice that have been fed with reduced coenzyme Q10 over a long period. Based on these findings, it was found that the composition containing reduce coenzyme Q10 as an active ingredient has potential to be a composition for life extension with high safety, capable of being taken for a long period.Type: ApplicationFiled: September 21, 2006Publication date: June 11, 2009Applicant: KANEKA CORPORATIONInventors: Hideyuki Kishida, Taizuo Kawabe, Kazunori Hosoe
-
Publication number: 20090142324Abstract: To provide an oil-in-water emulsion composition that prevents separation of coenzyme Q10 and creaming during storage, maintains a stable emulsification state over long term exceeding two weeks, and does not impair flavor or taste. The oil phase of the oil-in-water emulsion composition contains coenzyme Q10, and a complex of an organic acid ester of a monoglyceride and a milk protein is used as the emulsifier.Type: ApplicationFiled: February 3, 2009Publication date: June 4, 2009Inventors: Toshinori Ikehara, Koji Ogino
-
Patent number: 7537774Abstract: A pharmaceutical composition including a salt of rhodizonic acid, an OH anion-generating base, a non-toxic acid, a quinone, a salt-containing sulfite, catechol and, optionally, an acetogenin. The formulation demonstrates positive effects against cancer, autoimmune disease, viruses and provides antioxidant protection against peroxyl, hydroxyl and super oxide radicals.Type: GrantFiled: December 23, 2005Date of Patent: May 26, 2009Assignee: Orion Therapeautics, LLCInventor: Jerome Godin
-
Publication number: 20090130075Abstract: The present invention is drawn to an ephedra- and artificial stimulant-free energy promoting composition, comprising effective amounts of a magnesium amino acid chelate, a B vitamin, a pyruvate salt, and rhodiola. These ingredients work synergistically together to provide energy, without the use of artificial stimulants, caffeine, or ephedrine. Additional amino acid chelates can also be present, such as iron amino acid chelate, zinc amino acid chelate, copper amino acid chelate, manganese amino acid chelate, chromium amino acid chelate, and mixtures of second amino acid chelates.Type: ApplicationFiled: November 20, 2008Publication date: May 21, 2009Inventors: Janeel Henderson, DeWayne Ashmead
-
Patent number: 7531695Abstract: The present invention is directed to compounds having the structure (I) wherein R1, R2, R3, R4, R5 and m are as defined herein. The compounds of this invention are novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders in mammalian subjects. These compounds are also useful modulators of gene expression. They exert their activity by interfering with certain cellular signal transduction cascades. The compounds of the invention are thus also useful for regulating cell differentiation and cell cycle processes that are controlled or regulated by various hormones or cytokines. In particular, the invention relates to compounds that induce apoptosis of cancer cells and therefore may be used for the treatment or prevention of cancer, including advanced cancers and pre-cancerous cells. The invention also discloses pharmaceutical compositions and methods of treatment of disease in mammals.Type: GrantFiled: June 3, 2004Date of Patent: May 12, 2009Assignee: Auspex Pharmaceutical, IncInventors: Borcherng Hong, Sepehr Sarshar, Bruno Tse
-
Publication number: 20090087420Abstract: The present invention provides a composition of a practically usable solution capable of stably maintaining, against oxidation, reduced coenzyme Q, which has not been employed in practice so far because of being liable to undergo oxidation and hydrophobic, a method of preparing the solution and a method of storing the solution. A solution of reduced coenzyme Q which can be stored at a low temperature or room temperature over a long time can be prepared by coating reduced coenzyme Q with liposome made of refined soybean lecithin, etc, and solubilizing, or solubilizing or emulsifying reduced coenzyme Q by using a surfactant at a low temperature.Type: ApplicationFiled: December 4, 2008Publication date: April 2, 2009Applicant: Kaneka CorporationInventors: Kenji FUJII, Taizo Kawabe, Kazunori Hosoe, Takayoshi Hidaka
-
Publication number: 20090076169Abstract: Antimicrobial compositions and methods of using such antimicrobial compositions to provide a reduction in populations of viable microorganisms.Type: ApplicationFiled: September 19, 2007Publication date: March 19, 2009Inventors: Edwin Dean Neas, Thomas Boyd Gilligan
-
Publication number: 20090069442Abstract: The present invention provides therapeutic agents for sensory disorders represented by the following formula (1): [wherein R1, R2, and R3 each represent a hydrogen atom or a methyl group, and X represents a linear or branched C10-C28 alkylene or alkenylene group]. The cyclohexenone long chain alcohol of the present invention improves hyperalgesia or hypoalgesia, and thus is useful as therapeutic agents for sensory disorders. Sensory disorders that can be prevented or treated by the present invention include chronic intractable pain, neurogenic pain, reduction of pain threshold caused by nerve injuries, hypesthesia or hyperesthesia caused by diabetes and nerve injuries, and the like.Type: ApplicationFiled: January 18, 2006Publication date: March 12, 2009Inventors: Hirohito Shiomi, Yutaka Tamura, Bang Luu, Masashi Yamada, Keizou Koyama, Hiroto Suzuki
-
Patent number: 7501454Abstract: The present invention relates to a compound of Antrodia camphorata used to treat autoimmune diseases, in particular to an extract, 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone, isolated from Antrodia camphorata, and its use in alleviating symptoms of autoimmune diseases such as systemic lupus erythematosus (SLE). The cyclohexenone compound according to the present invention helps to decrease proteinuria levels and antinuclear antibody titers in SLE mammals in order to alleviate kidney inflammation and disease, as well as the self-damage caused by antinuclear antibodies. The purpose for prevention and treatment of autoimmune diseases and kidney diseases by the natural, side-effect free substance can then be accomplished.Type: GrantFiled: July 31, 2007Date of Patent: March 10, 2009Assignee: Golden Biotechnology CorporationInventors: Sheng-Yun Liu, Mao-Tien Kuo, Wu-Che Wen
-
Patent number: 7497901Abstract: Complexes of copper and/or zinc with molybdate and/or tungstate were solubilized in ammonia or ammoniacal solution providing preservative solutions that fully penetrate wood. With loss of the ammonia from the wood, the complexes were stably retained in the wood providing a long lasting preservative.Type: GrantFiled: December 21, 2006Date of Patent: March 3, 2009Assignee: E. I. dupont de Nemours and CompanyInventors: Albert Gordon Anderson, John Feaster, Damini Patel, Mark Scialdone
-
Publication number: 20090054524Abstract: The present invention provides methods and compositions for inhibiting IKK, as well as methods and compositions for identifying compounds with activity as inhibitors of IKK, and methods and compositions for the treatment of diseases and/or conditions wherein IKK is implicated and inhibition of its activity is desired. In addition, the present invention provides methods and compositions for the improving the therapeutic activity of COX2 inhibitors, comprising administering the COX2 to a subject in combination with a compound that inhibits IKK activity. The present invention further provides compositions that comprise compounds that inhibit IKK and COX2.Type: ApplicationFiled: July 9, 2008Publication date: February 26, 2009Inventors: Michael Karin, Pankaj Kapahi
-
Publication number: 20090042995Abstract: A pharmaceutical composition including a salt of rhodizonic acid, an OH anion-generating base, a non-toxic acid, a quinone, a salt-containing sulfite, catechol and, optionally, an acetogenin. The formulation demonstrates positive effects against cancer, autoimmune disease, viruses and provides antioxidant protection against peroxyl, hydroxyl and super oxide radicals.Type: ApplicationFiled: May 30, 2008Publication date: February 12, 2009Applicant: Orion Therapeutics, LLCInventor: Jerome Godin
-
Publication number: 20090030087Abstract: The present invention relates to pesticides. More particularly, the present invention relates to botanical pesticides. In particular, the present invention relates to compositions and methods for controlling plant-infesting pests with plant extracts and notably with compositions comprising oil extracts derived from Chenopodium sp. plant material. The invention further relates to compositions comprising such extracts as pesticidal compositions and providing the advantages of minimal development of resistance thereto, minimal toxicity to mammals, minimal residual activity and environmental compatibility. The pesticidal compositions of the present invention comprises ?-terpinene, ?-cymene, limonene, carvacrol, carveol, nerol, thymol, and carvone.Type: ApplicationFiled: February 11, 2008Publication date: January 29, 2009Inventor: Helene Chiasson
-
Publication number: 20090022786Abstract: The present invention provides an coated oral pharmaceutical dosage form comprising a composition of a non-steroidal anti-inflammatory drug (NSAID) as multilayered spherical granule combined with a composition of prostaglandin, and a film coating. The present invention also provides a method for manufacturing the dosage form, which comprising the steps of preparing the compositions of NSAID and prostaglandin separately, combing the compositions to form a pharmaceutical dosage form, and coating the dosage form with a film coating.Type: ApplicationFiled: January 30, 2008Publication date: January 22, 2009Inventors: Fang-Chen Lee, Bin-Ken Chen, Han-Chiang Kuo, Chi-Huang Chen
-
Publication number: 20090017136Abstract: The formulation provides for the treatment and prevention of fibromyalgia, depression and other muscle and nervous system disorders. The formulation combines Coenzyme Q10, vitamin B1, 5-Hydroxytryptophan, magnesium, Vitamin D, Vitamin C, Selenium and Zinc. Each component has an effect on its own combined with a synergistic effect with other components.Type: ApplicationFiled: July 10, 2007Publication date: January 15, 2009Inventor: Wayne Gorsek
-
Publication number: 20090012162Abstract: The invention relates to the use of a molecule selected from the group which consists of geranyl acetate, geraniol, isomenthone, limonene or a mixture of at least two of the above, for preparing a drug for treating or preventing vascular endothelial cell senescence and subjacent tissue degeneration induced by repeated inflammatory episodes. Specifically, the drug is useful for treating vascular endothelial cell senescence and tissue degeneration induced by repeated inflammatory episodes resulting from the presence of cancer cells.Type: ApplicationFiled: October 23, 2006Publication date: January 8, 2009Inventor: Patrizia D'Alessio
-
Publication number: 20090011059Abstract: The present invention relates to the use of a ginger extract on its own or in combination with pharmaceutical compositions for inhibiting human drug transporters for positively influencing the oral bioavailability and pharmacokinetics of active substances.Type: ApplicationFiled: December 20, 2006Publication date: January 8, 2009Inventors: Naoki Ishiguro, Wataru Kishimoto, Thomas Ebner, Willy Roth
-
Publication number: 20080317727Abstract: Compositions and methods for the prevention and treatment of skin and ocular rosacea using epidermal growth factor and an acceptable carrier are disclosed.Type: ApplicationFiled: May 2, 2006Publication date: December 25, 2008Inventors: Hannah Naomi Sivak, Artist Cloutier
-
Patent number: 7468392Abstract: The present invention relates to a compound of Antrodia camphorata used to delay physiological fatigue, in particular to a extract isolated from Antrodia camphorata, 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6-10-trienyl)-cyclohex-2-enone, and its use in delaying fatigue. Immediate supplementation of the compound according to the invention after high intensity exhausted exercise at 80% VO2max can promote the metabolism of creatine phosphate kinase and blood ammonia in human bodies, be beneficial to their recovery, further achieves the function in delaying physiological fatigue.Type: GrantFiled: July 27, 2007Date of Patent: December 23, 2008Assignee: Golden Biotechnology CorporationInventors: Sheng-Yun Liu, Mao-Tien Kuo, Wu-Che Wen
-
Publication number: 20080312336Abstract: The present invention provides preventive and/or therapeutic agents for either one, or both, of a diabetic vascular disorder and a diabetic respiratory disorder comprising, as an active ingredient, a cyclohexenone long chain alcohol compound represented by the following formula (1): [wherein R1, R2, and R3 each represent a hydrogen atom or a methyl group, and X represents a linear or branched C10-C28 alkylene or alkenylene group]. Since the cyclohexenone long chain alcohol of formula (1) improves diabetic vascular smooth muscle contraction and bronchial smooth muscle contraction, it is useful as a preventive and/or therapeutic agent for a diabetic vascular disorder or a respiratory disorder.Type: ApplicationFiled: November 24, 2005Publication date: December 18, 2008Inventors: Keisuke Satoh, Motoaki Saito, Bang Luu, Masashi Yamada, Hiroto Suzuki
-
Publication number: 20080312335Abstract: The present invention relates to a compound of Antrodia camphorata used for liver protection, in particular to an extract, 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone which is isolated from Antrodia camphorate. The cyclohexenone compound according to the invention helps to alleviate liver injury and fibrosis induced by chemicals and reduces the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). By increasing the contents of glutathione peroxidase (GSHPX) and catalase (CAT), cyclohexenone further decreases the liver damage and the oxidative pressure caused by free radicals, enhances the antioxidant ability and achieves the purposed of liver protection.Type: ApplicationFiled: September 24, 2007Publication date: December 18, 2008Inventors: Sheng-Yun Liu, Wu-Che Wen, Mao-Tien Kuo
-
Publication number: 20080312334Abstract: The present invention relates to a compound of Antrodia camphorata used to treat autoimmune diseases, in particular to an extract, 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone, isolated from Antrodia camphorata, and its use in alleviating symptoms of autoimmune diseases such as systemic lupus erythematosus (SLE). The cyclohexenone compound according to the present invention helps to decrease proteinuria levels and antinuclear antibody titers in SLE mammals in order to alleviate kidney inflammation and disease, as well as the self-damage caused by antinuclear antibodies. The purpose for prevention and treatment of autoimmune diseases and kidney diseases by the natural, side-effect free substance can then be accomplished.Type: ApplicationFiled: July 31, 2007Publication date: December 18, 2008Applicant: Golden Biotechnology CorporationInventors: Sheng-Yun Liu, Mao-Tien Kuo, Wu-Che Wen
-
Patent number: 7456225Abstract: The present invention relates to a compound of Antrodia camphorata used for liver protection, in particular to an extract, 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone which is isolated from Antrodia camphorata. The cyclohexenone compound according to the invention helps to alleviate liver injury and fibrosis induced by chemicals and reduces the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). By increasing the contents of glutathione peroxidase (GSHPx) and catalase (CAT), cyclohexenone further decreases the liver damage and the oxidative pressure caused by free radicals, enhances the antioxidant ability and achieves the purposed of liver protection.Type: GrantFiled: September 24, 2007Date of Patent: November 25, 2008Assignee: Golden Biotechnology CorporationInventors: Sheng-Yun Liu, Wu-Che Wen, Mao-Tien Kuo
-
Publication number: 20080254140Abstract: Described herein are combination methods, compositions and therapies for treating ophthalmic conditions or diseases arising from, associated with or leading to the overproduction of waste products in the visual cycle. Agents included within these combinations are 13-cis-retinyl derivatives; other agents included within these combinations are selected from vitamins, antioxidants, minerals, inducers of nitric oxide production, anti-inflammatory agents, and negatively-charged phospholipids. Such combination methods may be used as single or multiple administration therapies, or in combination with other agents or therapies.Type: ApplicationFiled: August 18, 2005Publication date: October 16, 2008Inventors: Kenneth Widder, Jay Lichter
-
Patent number: 7431940Abstract: Methods for treatment of human skin damaged by laser treatment or chemical peelings comprise the topical application of an effective amount of a lamellar oil-in-water system. In accordance with the methods, the lamellar oil-in-water system comprises at least one vegetable oil as the oily component, a hydrogenated phospholipid as emulsifier comprising not more than 10 percent by weight of negatively charged phospholipids with the remainder being neutral phospholipids, and sodium carboxymethyl ?-glucan (Sodium Carboxymethyl Betaglucan) as a compound for improving wound healing. The lamellar oil-in-water system used in the method may further comprise coenzyme Q10 as a compound for improving skin regeneration.Type: GrantFiled: November 18, 2004Date of Patent: October 7, 2008Assignee: Mibelle AG CosmeticsInventors: Fred Zülli, Margrit Neuenschwander, Nicola Cardozo-Hofmann
-
Publication number: 20080234386Abstract: The present invention is directed to pest-controlling compositions comprising as active ingredients one or more ?-diones, particularly ?-diketones and ?-triketones, and to the use of these compositions inter alia for preventing, eradicating, destroying, repelling or mitigating harmful, annoying or undesired pests including insects, arachnids, helminths, molluscs, protozoa and viruses. The present invention is further directed to processes of preparing ?-diones by de novo synthesis or from natural sources such as volatile oil-bearing plants from families including Alliaceae, Apiaceae, Asteraceae, Cannabinaceae, Lamiaceae, Pteridaceae, Myrtaceae, Myoporaceae, Proteaceae, Rutaceae and Zingiberaceae.Type: ApplicationFiled: June 5, 2008Publication date: September 25, 2008Applicant: Bioprospect LimitedInventors: Robert Neil Spooner-Hart, Albert Habib Basta
-
Publication number: 20080233145Abstract: Pharmaceutical compositions of Usnea barbata and the use thereof for the treatment of skin diseases are disclosed. A preferred composition is the combination with an extract of Hypericum perforatum. The extracts are obtained by supercritical high-pressure extraction with spring carbon-dioxide. A preferred form of preparation is the homogenization of 6% by weight of an extract of Usnea barbata, containing 96% of usnic acid, and 40% by weight of an extract of Hypericum perforatum, containing 39% of hyperforin, together. The pharmaceutical composition leads to a potentiation of the anti-inflammatory and anti-microbial effects of the extracts and to stabilization of the hyperforin. The combination is suitable for the external and internal treatment of various skin diseases, in particular skin inflammations and skin ageing, and for the treatment of skin infections with pityrosporon yeast fungi, acne and rosacea.Type: ApplicationFiled: April 7, 2005Publication date: September 25, 2008Applicant: UNIVERSITÄTSKLINIKUM FREIBURGInventors: Christoph Mathis Schempp, Andrea Jocher, Kathrin Engel, Constance Huyke
-
Patent number: 7427316Abstract: Complexes of tropolone and copper and/or zinc were solubilized in ammoniacal solution providing preservative solutions that fully penetrate wood. With loss of the ammonia from the wood, the complexes were stably retained in the wood providing a long lasting preservative.Type: GrantFiled: December 21, 2006Date of Patent: September 23, 2008Assignee: E.I. du Pont de Nemours and CompanyInventors: Albert Gordon Anderson, John Feaster, Damini Patel, Mark Scialdone
-
Publication number: 20080220038Abstract: There is disclosed method of killing nematodes comprising the step of applying an effective amount of a nematicidal composition comprising a terpene component and compositions suitable for use in the method. The terpene component is preferably in association with water, either as a solution or a suspension. An excipient may also be included, which is suitably hollow glucan particles which encapsulate the terpene component.Type: ApplicationFiled: January 24, 2005Publication date: September 11, 2008Inventors: Lanny Franklin, Elizabeth Cloud, Lanna Knapp, Gary Ostroff
-
Patent number: 7417072Abstract: The invention provides pharmaceutical compositions and methods of treating immunological disorders. The invention also provides pharmaceutical compositions and methods of inducing eosinophil apoptosis, and methods for treating eosinophil-associated disorders comprising inducing eosinophil apoptosis in an individual in need thereof.Type: GrantFiled: May 12, 2006Date of Patent: August 26, 2008Assignee: Wisconsin Alumni Research FoundationInventors: James S. Malter, Stephane Esnault, Zhong-Jian Shen
-
Publication number: 20080200558Abstract: A method for inhibiting or blocking molecular generating and/or inducing functions of molecules using an inhibitory or blocking agent of the formula: wherein R1-6 are as defined herein.Type: ApplicationFiled: August 9, 2007Publication date: August 21, 2008Inventors: Shozo Koyama, Yoshihiro Yamaguchi
-
Patent number: 7411003Abstract: The present invention relates to a compound of Antrodia camphorata used to inhibit HBV, in particular to an extract, 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone which is isolated from Antrodia camphorata, and its use in inhibiting HBV effectively. The cyclohexenone compound according to the present invention showed cytotoxicity on HBV-secreting human hepatoma cell line HepG2 2.2.15, decreased synthesis of HBV particles, further inhibited synthesis of HbsAg and HbeAg effectively to achieve the goal of HBV inhibition.Type: GrantFiled: August 21, 2007Date of Patent: August 12, 2008Assignee: Golden Biotechnology CorporationInventors: Sheng-Yun Liu, Mao-Tien Kuo, Wu-Che Wen
-
Patent number: 7399888Abstract: The invention relates to novel isoxylitones and their use as anticonvulsant and in the treatment of a variety of disorders.Type: GrantFiled: July 1, 2006Date of Patent: July 15, 2008Assignee: HEJ Research Institute Karachi UniversityInventors: Attaur Rahman, Mohammad Iqbal Choudhary, Farzana Shaheen, Arun Ganesan, Shabana Usman Simjee, A. Mohsin Raza
-
Publication number: 20080145411Abstract: The present invention provides a method of increasing the absorbability of oxidized coenzyme Q10 by preparing the oxidized coenzyme Q10 as a composition in the presence of a lysolecithin and an oil and fat. The composition of the present invention comprising oxidized coenzyme Q10, a lysolecithin and an oil and fat, wherein the weight ratio of the lysolecithin to the oxidized coenzyme Q10 is not less than 0.7, shows superior absorption of oxidized coenzyme Q10 and can be utilized for food, food with nutrient function, food for specified health uses, nutritional supplement, nutritional product, animal drug, beverage, feed, pet food, cosmetics, pharmaceutical product, therapeutic drug, preventive drug and the like.Type: ApplicationFiled: October 4, 2007Publication date: June 19, 2008Applicant: KANEKA CORPORATIONInventors: Yoshiyuki Shinagawa, Taizo Kawabe, Hideyuki Kishida, Kazunori Hosoe
-
Patent number: 7385088Abstract: The present invention relates to a novel compound and use thereof, in particular to Antroquinonol B and Antroquinonol C isolated from Antrodia camphorata extracts which can effectively inhibit the growth of cancer cells. The compounds from Antrodia camphorata are first reported, which can be applied not only in inhibiting growth of breast cancer, lung cancer, hepatic cancer and prostate cancer, but also in anti-cancer medicinal compositions for the abovementioned cancer cells.Type: GrantFiled: January 29, 2008Date of Patent: June 10, 2008Assignee: Golden Biotechnology CorporationInventors: Sheng-Yun Liu, Mao-Tien Kuo, Wu-Che Wen
-
Publication number: 20080132568Abstract: Compounds having anti-androgenic activities are disclosed. Further disclosed are methods of using the compounds to prevent or treat androgen-dependent diseases or to provide nutraceutical benefits. Pharmaceutical and nutraceutical compositions containing the anti-androgenic compounds are also disclosed.Type: ApplicationFiled: November 8, 2007Publication date: June 5, 2008Inventors: Todd A. Thompson, Debra A. MacKenzie
-
Patent number: 7378557Abstract: A method for making isolongifolenone involving reaction (?)-isolongifolene with chromium hexacarbonyl and t-butyl hydroperoxide. Also the use of isolongifolenone to repel arthropods by treating an object or area with an arthropod repelling effective amount of isolongifolenone (and optionally a carrier or carrier material).Type: GrantFiled: July 13, 2007Date of Patent: May 27, 2008Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Aijun Zhang, John Carroll, Shifa Wang, Jerome A. Klun
-
Publication number: 20080118591Abstract: The invention relates to bactericidal formulations that come into contact with human body, particularly wash formulations including liquid soaps, comprising perfume ingredients active against gram-negative bacteria. Such compositions contact the target site, for example the skin surface, only for a short time, usually not longer than 30 seconds. Therefore the antibacterial action has to be of the bactericidal type and rapid. Furthermore, the bactericidal activity has to be sufficiently high to ensure an effect even when applied to wet substrates that will dilute the bactericidal formulation.Type: ApplicationFiled: November 15, 2005Publication date: May 22, 2008Inventor: Andreas Natsch
-
Patent number: 7374901Abstract: The present invention relates to an analysis method and analysis system that can accurately analyze the contents of coenzyme Q-10 and a 2-electron reduced form thereof in a specimen, in which human blood plasma as the specimen is mixed with isopropyl alcohol as a pretreatment and the coenzyme Q-10 and the 2-electron reduced form thereof are extracted to the isopropyl alcohol. Extracted liquid is stored at a temperature of 4° C. until the analysis is performed. The extracted liquid as an analytical sample is analyzed by an analysis system provided with a liquid-sending mechanism, a switching mechanism, a concentration column, a separation column, a reduction column, an ultraviolet absorption detector, and an electrochemical detector.Type: GrantFiled: December 3, 2003Date of Patent: May 20, 2008Assignee: Shiseido Company Ltd.Inventors: Yorihiro Yamamoto, Masashi Mita